SCHEMBL4030294

SCHEMBL4030294

CN(C)C(=O)CC(c1ccc(OC(F)F)c(OC(F)F)c1)N1C(=O)c2[c]cccc2C1C(N)=O

nearest known ligand 0.34

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
TNF P01375 9/20 0.34
PDE4A P27815 11/20 0.33
PDE4B Q07343 10/20 0.33
PDE4C Q08493 10/20 0.33
PDE4D Q08499 10/20 0.33
MEN1 O00255 1/20 0.30
GAA P10253 1/20 0.30
KMT2A Q03164 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4025658 0.95 TNF (0.41) TNFPDE4APDE4BPDE4CPDE4D
SCHEMBL4031151 0.91 TNF (0.40) TNFPDE4APDE4BPDE4CPDE4D
SCHEMBL2979242 0.88 TNF (0.49) TNFPDE4APDE4BPDE4CPDE4D
SCHEMBL4024737 0.87 TNF (0.35) TNFPDE4APDE4BPDE4CPDE4D
SCHEMBL1143842 0.85 TNF (0.40) TNFPDE4APDE4BPDE4CPDE4D
SCHEMBL2966972 0.82 PDE4B (0.45) PDE4APDE4BPDE4CPDE4D
SCHEMBL3554026 0.77 PDE4A (0.50) TNFPDE4APDE4BPDE4CPDE4D
SCHEMBL5671322 0.77 TNF (0.35) TNFPDE4APDE4BPDE4CPDE4D
SCHEMBL15252404 0.77 PDE4A (0.46) TNFPDE4APDE4BPDE4CPDE4D
Hydrochloric Acid SCHEMBL3553807 0.76 PDE4A (0.45) TNFPDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1587474-B1 FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES CELGENE CORP (US) 2009-11-18 EP claimed
US-20070072902-A1 Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses TRIMERIS, INC. 2007-03-29 US claimed
US-7173058-B2 Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses CELGENE CORPORATION (US) 2007-02-06 US claimed
US-20040204448-A1 Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses CELGENE CORPORATION 2004-10-14 US claimed
EP-1587474-B1 FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES CELGENE CORP (US) 2009-11-18 EP disclosed
US-20090143382-A1 FLUOROALKOXY-SUBSTITUTED 1,3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES CELGENE CORPORATION 2009-06-04 US disclosed
US-7504427-B2 Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses CELGENE CORPORATION (US) 2009-03-17 US disclosed
US-20070072902-A1 Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses TRIMERIS, INC. 2007-03-29 US disclosed
US-7173058-B2 Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses CELGENE CORPORATION (US) 2007-02-06 US disclosed
EP-1587474-A4 FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES CELGENE CORP (US) 2006-11-22 EP disclosed
EP-1587474-A2 FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES CELGENE CORPORATION (US) 2005-10-26 EP disclosed
EP-1587474-A3 FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES CELGENE CORPORATION (US) 2005-09-15 EP disclosed
US-20040204448-A1 Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses CELGENE CORPORATION 2004-10-14 US disclosed
WO-2004060313-A2 FLUOROALKOXY-SUBSTITUTED 1, 3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES CELGENE CORPORATION (US) 2004-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143382-A1 FLUOROALKOXY-SUBSTITUTED 1,3-DIHYDRO-ISOINDOLYL COMPOUNDS AND THEIR PHARMACEUTICAL USES PDE4A, PDE4B, PDE4D TNF 4126/4885PDE4A 1/4885PDE4B 2/4885
US-20070072902-A1 Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses PDE4A, PDE4B, PDE4D TNF 4126/4885PDE4A 1/4885PDE4B 2/4885
US-20040204448-A1 Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses PDE4A, PDE4B, PDE4D TNF 4126/4885PDE4A 1/4885PDE4B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.